Tesamorelin cost in the Netherlands

Searching for the price of tesamorelin in the Netherlands leads to the same structural answer: there is no official price to report. The European Medicines Agency (EMA) never granted tesamorelin a marketing authorisation. Theratechnologies' European partner Ferrer Internacional withdrew the application on 21 June 2012 after the CHMP concluded the benefits of Egrifta did not outweigh its risks^[1]. No authorisation means no pharmacy shelf price, no listing in the Geneesmiddelenvergoedingssysteem (GVS), no Zorgverzekeringswet (ZVW) reimbursement, and no reference price under the Wet geneesmiddelenprijzen (WGP). What exists instead is an unregulated grey market and the FDA-approved branded product available, legally, only through a named-patient import route arranged by a prescribing clinician.

This article explains what happened in 2012, what the gap means for Dutch patients today, what grey-market suppliers charge, how the approved medicines on the Netherlands regulation page compare in cost, and what reimbursement would require if a future application succeeded. For the full tesamorelin clinical profile and global regulatory map, see the tesamorelin peptide page.

Why tesamorelin has no official price in the Netherlands

In the Netherlands, a medicine can only carry an official price after it receives a marketing authorisation. The Geneesmiddelenwet (Gmw, Medicines Act, 2007) requires that any finished medicinal product hold a valid marketing authorisation before it is placed on the Dutch market^[2]. Once a medicine is authorised, the Wet geneesmiddelenprijzen (WGP) sets a maximum retail price by benchmarking the product against four reference countries: Belgium, France, Germany, and the United Kingdom. The Zorginstituut Nederland then assesses whether the medicine qualifies for inclusion in the GVS national reimbursement list. Every step in that chain presupposes an authorisation that tesamorelin does not have.

Tesamorelin reached the EMA authorisation process only once. Ferrer Internacional submitted the application for Egrifta for excess abdominal fat in HIV-infected patients with lipodystrophy. The CHMP concluded after review that the abdominal fat reduction the drug produced had not been shown to be clinically meaningful in terms of actual health benefits to patients, that study populations were not representative of European HIV patients, and that elevated IGF-1 levels in a considerable number of treated patients raised cancer and diabetic-complication concerns without long-term safety data to characterise them^[1]. Ferrer acknowledged the CHMP's position and formally withdrew the application on 21 June 2012. No re-application has followed.

This outcome contrasts directly with the US situation. The FDA approved Egrifta (tesamorelin 1 mg, then the reformulated Egrifta SV 2 mg) for HIV-associated lipodystrophy in 2010, on the basis of two key Phase 3 trials showing visceral adipose tissue reduction in that specific patient population. That approval, for a narrow licensed indication, is the only marketing authorisation tesamorelin holds anywhere in the world. The US and the EU reviewed the same molecule and reached different conclusions, partly on the basis of differences in study population representativeness and how they weighted the benefit-risk balance in a condition where the clinical meaningfulness of visceral fat reduction was contested.

The named-patient route: lawful but not a price

The Netherlands, like other EU member states, has a provision for unlicensed medicines under the Geneesmiddelenwet^[2]. A prescribing clinician can request an unlicensed import of an authorised foreign medicine for a specific named patient when no authorised equivalent is available in the Netherlands and the clinical need is documented. In principle, a Dutch clinician treating a patient with HIV-associated lipodystrophy could request Egrifta SV through this named-patient route. The clinician would take responsibility for the prescription, the product would be imported at cost, and the patient would not have GVS reimbursement available because there is no GVS listing for tesamorelin.

In practice, this route is rarely used for tesamorelin in the Netherlands. The indication (HIV-associated lipodystrophy) is narrow, HIV treatment has evolved to produce less lipodystrophy with modern antiretroviral regimens than with older regimens, and the drug's cost via named-patient import is carried by the patient or the hospital budget rather than the basic health insurance package. No verified list price for Egrifta through a Dutch named-patient import channel was available at time of publication. The US list price for Egrifta SV has been reported in US pharmacy benefit contexts at several thousand US dollars per month, before any patient assistance programmes. Dutch named-patient import pricing does not track US list prices and is negotiated case by case with the importing pharmacy. The tesamorelin history page covers the Theratechnologies development arc and how the US and EU approval paths diverged.

PeptideMethods cannot confirm a Netherlands named-patient price for tesamorelin. No verified list price data was available at time of publication. Any patient or clinician exploring this route should contact a Dutch hospital pharmacy with experience in unlicensed-medicine imports and verify costs directly. For the broader legal picture across EU jurisdictions, see the tesamorelin is it legal page.

What the clinical evidence for tesamorelin shows

The evidence base for tesamorelin is narrow in scope but genuine in quality within that scope. A 2026 meta-analysis by Badran and colleagues, covering five randomised controlled trials in patients with HIV-associated lipodystrophy, found that tesamorelin produced a mean visceral adipose tissue reduction of 27.71 cm², a 1.42 kg gain in lean body mass, a 4.28% decline in hepatic fat percentage, and a 1.61 cm reduction in waist circumference^[3]. The meta-analysis reported no serious adverse events at the group level, with the main signals being arthralgia, myalgia, paresthesia, and injection-site reactions.

What the evidence does not cover is the off-label use context that drives most of the online interest in tesamorelin: body composition improvement in people without HIV, sleep enhancement, or anti-ageing applications. The trial record supporting FDA approval was built entirely in HIV-associated lipodystrophy^[3]. Off-label uses have not been studied in placebo-controlled trials, the IGF-1 elevation concern applies outside the approved indication as well as within it, and the EMA's 2012 concerns about long-term safety data remain unaddressed in the broader sense. See the tesamorelin side effects page for the full safety profile.

Grey-market costs: what suppliers charge

Tesamorelin is available through grey-market research-chemical vendors and some international compounding operations, ahead of any EU authorisation, any pharmacopoeial quality standard, and any GMP-compliant supply chain for the European market. These products are not authorised medicines in the Netherlands or the EU. See the tesamorelin grey-market risks page for a detailed breakdown of what independent testing has found.

Grey-market pricing for tesamorelin varies and shifts frequently. Across international research-chemical markets, vials or kits described as tesamorelin appear at prices ranging roughly from 30 to 150 euros per vial depending on the claimed content, purity, and vendor location. These figures come from observed market listings and carry no quality assurance. The quality concern is material: independent testing of grey-market peptides has found identity failures, mislabelled concentrations, and bacterial contamination. There is no pharmacopoeial monograph for tesamorelin available to buyers for independent verification, outside of the specific Egrifta SV formulation that the FDA-approved manufacturer produces. For a comparison with another GHRH analogue that circulates in the same grey-market channels, see the CJC-1295 vs tesamorelin page.

PeptideMethods does not facilitate the sale of any peptide product and does not endorse grey-market sourcing. The price ranges above are observations about market listings, not a recommendation to purchase.

How approved medicines compare in cost in the Netherlands

To give Dutch readers a cost anchor, it helps to look at the GLP-1 class medicines that have successfully navigated the Dutch pricing and reimbursement system. Both semaglutide and tirzepatide received EMA marketing authorisations, went through the WGP benchmarking process, and have GVS assessments on record^[4][5].

Ozempic (semaglutide for type-2 diabetes) is listed in the GVS and reimbursed for qualifying patients. Wegovy (semaglutide 2.4 mg for weight management) is authorised but faced a more restricted GVS listing: Zorginstituut Nederland concluded the cost-effectiveness evidence did not meet the threshold for unconditional inclusion at launch^[5]. Dutch patients accessing Wegovy privately pay in the range of 250 to 350 euros per month for the maintenance dose. Mounjaro (tirzepatide) for type-2 diabetes has a GVS listing under conditions similar to those applied to other GLP-1 agents; the weight-management indication faces tighter access criteria. Private patients paying for Mounjaro for weight management pay roughly 250 to 400 euros per month depending on dose^[4]. For a detailed breakdown of semaglutide costs in the Netherlands, see the semaglutide Netherlands cost page.

These prices exist because those medicines have EMA authorisations, have gone through WGP maximum-price calculations, and have Zorginstituut assessments. Tesamorelin cannot access any of these steps without first obtaining a marketing authorisation it does not hold. For context on tirzepatide costs, see the tirzepatide Netherlands cost page.

What a future reimbursement path would require

For tesamorelin to reach the Dutch reimbursement system, a sponsor would need to submit a new Marketing Authorisation Application to the EMA. The CHMP would review it and issue a positive opinion. The European Commission would convert that opinion into a marketing authorisation. The WGP would calculate a maximum retail price. The Zorginstituut would conduct a GVS assessment. And a listing decision would follow, with or without conditions^[2]. Each step takes months.

The 2012 withdrawal creates a specific challenge for any future application. The EMA's concerns at withdrawal, about clinical meaningfulness of visceral fat reduction, patient population representativeness, and IGF-1 safety, would need to be addressed with new data. Antiretroviral therapy has evolved significantly since the key trials that supported FDA approval, which means the patient population available for a new EU-focused trial would look different from the original programme. A sponsor seeking EU authorisation now would need to design a trial addressing the specific concerns the CHMP raised. No sponsor has publicly announced any intention to do this.

The Netherlands has historically applied tight cost-effectiveness thresholds for medicines with narrow indications. Even if an EU application succeeded, the Zorginstituut would assess cost per QALY against Dutch health economics standards. Whether tesamorelin in HIV-associated lipodystrophy would meet that threshold is not something the current data can answer. The comparison with how semaglutide's Netherlands reimbursement played out shows how carefully Zorginstituut weighs cost-effectiveness before confirming unconditional GVS inclusion.

What we do not yet know

The situation as of July 2026 is straightforward on the regulatory facts and less clear on everything downstream. No EU marketing authorisation exists. No sponsor has announced a plan to apply. No Dutch GVS listing has ever existed. No verified Dutch named-patient price is publicly available. The tesamorelin dosing literature page covers what the trial record says about doses and duration in the approved HIV-lipodystrophy context.

We will update this page if the regulatory picture changes. The signal to watch is an announcement of a new EMA application from Theratechnologies or any acquirer of the European rights to the compound. For the country-by-country status of tesamorelin across all jurisdictions the site tracks, see the tesamorelin regulation section. For the full clinical profile including the FDA-approved indication, see the tesamorelin peptide page. If you are considering tesamorelin for any reason, speak with a clinician who knows your history before proceeding.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tesamorelin has no marketing authorisation in the Netherlands or the EU. Always consult a qualified healthcare professional before considering any medicine. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of the regulatory status as of July 2026. Regulations change. Verify with the CBG-MEB or a qualified professional before making any decision based on this article.